Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
US6841549B1 · kind B1 · utility
Assignee
Inventors
- Osamu Asano
- Hitoshi Harada
- Seiji Yoshikawa
- Nobuhisa Watanabe
- Takashi Inoue
- Tatsuo Horizoe
- Nobuyuki Yasuda
- Kaya Ohashi
- Hiroe Minami
- Junsaku Nagaoka
- Manabu Murakami
- Seiichi Kobayashi
- Isao Tanaka
- Tsutomu Kawata
- Naoyuki Shimomura
- Hiroshi Akamatsu
- Naoki Ozeki
- Toshikazu Shimizu
- Kenji Hayashi
- Toyokazu Haga
- Shigeto Negi
- Toshihiko Naito
Key dates
| Filing date | Jun 30, 2000 |
| Grant date | Jan 11, 2005 |
| Priority date | — |
| Expiry date | Jul 19, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D473/40
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention provides a preventive or therapeutic agent for diabetes mellitus and diabetic complications, which is a new type based on an adenosine A2 receptor antagonist action.That is, it provides a novel condensed imidazole compound which has an adenosine A2 receptor antagonist action, is effective for preventing or treating diabetes mellitus and diabetic complications, and is represented by the formula (I); (wherein R1 represents e.g. an amino group which may be substituted with an alkyl group; R2 represents e.g. hydrogen atom, an alkyl group, a cycloalkyl group or an alkyl group, alkenyl group or alkynyl group which may be substituted with hydrox etc.; R3 represents e.g. an optionally substituted alkyl group, alkenyl group, alkynyl group, aryl group, heteroaryl group, pyridinone group, pyrimidinone group or piperadinone group; Ar represents e.g. an optionally substituted aryl or heteroaryl group; and Q and W are the same as or different from each other and each represents N or CH), a pharmacologically acceptable salt or hydrates thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.